Physician profile
George Skandamis
NPI 1366561292
$18,409.20
in general payments reported to CMS, 2019-2025
38 companies · $1,871 in 2025
The $1,871 reported for 2025 was more than what 76% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,573 · 2020: $1,770 · 2021: $2,434 · 2022: $2,800 · 2023: $5,126 · 2024: $1,836 · 2025: $1,871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,293 · Consulting Fee: $2,800 · Education: $384 · Travel and Lodging: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,293.09 |
| Consulting Fee | $2,800.00 |
| Education | $384.42 |
| Travel and Lodging | $355.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $4,125.31 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Abbvie INC. | $3,622.08 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,680.74 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $906.90 | 2019-2025 | |
| Ucb, INC. | $872.11 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $858.50 | 2019-2025 | |
| Lilly USA, LLC | $720.40 | 2019-2025 | Ebglyss |
| Galderma Laboratories, L.P. | $688.20 | 2019-2025 | Nemluvio, Epsolay, Oracea |
| Journey Medical Corporation | $569.54 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $488.53 | 2019-2024 | Arazlo, Cabtreo |
| Amgen INC. | $443.01 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $403.49 | 2019-2025 | Libtayo, Dupixent |
| Leo Pharma INC. | $390.84 | 2020-2024 | Adbry |
| Merz North America, INC. | $268.98 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $247.32 | 2022-2025 | Sotyktu |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $239.10 | 2022-2024 | Vtama |
| Prugen, INC. Pharmaceuticals | $226.56 | 2019-2020 | |
| Pfizer INC. | $198.21 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $170.18 | 2020-2021 | |
| Incyte Corporation | $131.39 | 2021-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.24 | 2022-2024 | Spevigo |
| Organon LLC | $128.81 | 2025 | Vtama, Nexplanon |
| Almirall LLC | $119.26 | 2019-2025 | Seysara |
| Biofrontera INC. | $103.81 | 2019-2025 | Ameluz |
| Genentech USA, INC. | $102.93 | 2019-2024 | Xolair |
| Arcutis Biotherapeutics, INC. | $92.68 | 2023 | |
| Dermira, INC. | $91.47 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $89.59 | 2020-2024 | |
| Fresenius Kabi USA, LLC | $58.11 | 2023 | Idacio |
| Verrica Pharmaceuticals INC. | $47.41 | 2023-2024 | Ycanth |
| Epi Health, LLC | $37.66 | 2019-2020 | |
| Aclaris Therapeutics, INC. | $31.37 | 2019 | |
| Angiodynamics, INC. | $30.71 | 2019 | |
| Medline Industries Lp | $28.93 | 2020 | |
| Krystal Biotech INC | $22.50 | 2023 | Vyjuvek |
| Botanix Sb INC | $17.73 | 2025 | Sofdra |
| Mylan Pharmaceuticals INC. | $11.90 | 2019 | |
| Celgene Corporation | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Skandamis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.